A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

This Phase 1 study is testing a new drug called ZE50-0134 in people with relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or related low-grade lymphomas that have come back after multiple prior treatments. **You may be eligible if...** - You are 18 or older - You have CLL, SLL, or a related low-grade lymphoma (marginal zone lymphoma, Waldenstrom's macroglobulinemia, etc.) that has returned or stopped responding to treatment - You have already tried standard therapies including a BTK inhibitor (like ibrutinib or acalabrutinib) and venetoclax (or chose not to take it) - Your cancer is still causing symptoms **You may NOT be eligible if...** - You have not yet tried a BTK inhibitor - You have conditions that would make participation unsafe - Your cancer type is not covered under the study eligibility Talk to your doctor to see if this trial is right for you.